Results 41 to 50 of about 630,325 (166)

Characterization of FcRn knockout podocytes.

, 2019
A, Conditionally immortalized wild type (WT) and FcRn knockout (KO) podocytes express the podocyte markers podocin and Wilms Tumor 1 (WT1). Scale bar 20 μm. B, FcRn KO podocytes have minimal expression of FcRn mRNA.
Linda Lewis (6407513), Judith Blaine (277407), Pantipa Tonsawan (6407516), Parmjit S. Jat (634721), Makoto Miyazaki (316683), Evgenia Dobrinskikh (252465), James Dylewski (6407510)   +6 more
core   +1 more source

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report

Therapeutic Advances in Neurological Disorders
In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical
Isabelle Kwiedor, Martina Menacher, Monika Ellßel, Markus Naumann, Antonios Bayas   +4 more
doaj   +1 more source

Efgartigimod combined with steroids as a fast-acting therapy for anti-SRP immune-mediated necrotizing myopathy

Frontiers in Neurology
BackgroundImmune-mediated necrotizing myopathy (IMNM) is a rare autoimmune disease. Efgartigimod is a human IgG antibody Fc fragment, can enhance the degradation of IgG and thus may be a promising therapeutic agent for IMNM.MethodsAll three patients ...
Qiqi Peng, Xiaoping Yao, Sheng Chen, Xiaofeng Li, Feifei Lin, Zhangyu Zou   +5 more
doaj   +1 more source

Treatment‐driven peripheral blood transcriptomic remodelling and baseline predictors of ESSDAI and STAR response to B‐cell therapy in Sjögren's disease

Arthritis &Rheumatology, Accepted Article.
Objective To characterise whole‐blood transcriptomic profiles in adults with active Sjögren's disease (SjD) treated with anti‐CD20 or BlyS/BAFF inhibition, identify markers of clinical response, and define inflammatory pathways linked to non‐response. Methods Whole‐blood RNA sequencing was performed at baseline and week‐24 in participants (n=43) from a
Aimen Ibrahim, Junjie Peng, Eileen Tian, Lucia Martin‐Gutierrez, John Casement, Kyle Thompson, Wan‐Fai Ng, André van Maurik, Elizabeth C Jury, Coziana Ciurtin   +9 more
wiley   +1 more source

FcRn-mediated transcytosis and transport of Fc-fused IL-7 into serum after intravaginal treatment from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells

, 2016
Supplementary Figure 2.
Yong Bok Seo (8605218), Moon Cheol Kang (6738044), Dong-Hoon Choi (3365822), You Suk Suh (15006842), Yunji Park (15006839), Hong Namkoong (16898), Seung-Woo Lee (546107), Hyun-Tak Jin (357487), Young Chul Sung (14905080), Young Woo Choi (14993544)   +9 more
core   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Monitoring pharmacodynamic and molecular drug targets in liquid biopsy: Exploratory study in liver cancer with modelling of EGFR Receptor engagement

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Liquid biopsy is minimally invasive (compared with tissue biopsy) and has previously been used to generate systems data regarding drug elimination via hepatic enzymes and transporters. This study extends quantitative assessment of systems parameters in liquid biopsy to pharmacodynamic (PD) and disease markers relevant to cancer development
Zubida M. Al‐Majdoub, Armin Sepp, Amin Rostami‐Hodjegan, Brahim Achour   +3 more
wiley   +1 more source

Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network

Frontiers in Immunology
ObjectiveTo integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors ...
Luqiong Wang, Jiaojiao Chen, Huixiang Li, Lin Wang, Feiyu Liu, Xiaoli Jiang   +5 more
doaj   +1 more source

Recent Advances (2023–2025) of Capillary Electrophoresis‐Mass Spectrometry (CE‐MS) for Top‐Down Proteomics

Mass Spectrometry Reviews, EarlyView.
ABSTRACT Top‐down proteomics (TDP) characterizes proteoforms in cells, tissues, and biofluids, in discovery mode and on a global scale, requiring analytical tools with high peak capacity for proteoform separation and high sensitivity for proteoform detection, given the extremely high proteoform complexity and wide proteoform concentration dynamic range.
Guijie Zhu, David A. Alvarez Rodriguez, Noah Gould, Alexander R. Ivanov, Kevin Jooß, Liangliang Sun   +5 more
wiley   +1 more source

Management of Refractory Thymoma‐Associated Myasthenia Gravis With Sequential FcRn Antagonist and Complement Inhibition Combined With Resection of Pleural Dissemination

Neurology and Clinical Neuroscience, EarlyView.
ABSTRACT Myasthenia gravis (MG) associated with disseminated thymoma is often refractory to conventional treatments due to continuous autoantibody production. The optimal treatment strategy, particularly the combination of complement component 5 (C5) inhibitor, neonatal Fc receptor (FcRn) antagonist, and surgical resection in thymoma‐associated ...
Hiroyuki Takenaka, Madoka Iida, Yuki Fukami, Masahisa Katsuno   +3 more
wiley   +1 more source